Patents by Inventor Mark Semenuk

Mark Semenuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES
    Publication number: 20230032624
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Application
    Filed: May 9, 2022
    Publication date: February 2, 2023
    Inventors: Xiulian DU, Janos LUKA, Lewis Joe STAFFORD, Mark Semenuk, Xue-Ping WANG, Judith KANTOR, Andrew BRISTOL
  • Colon and pancreas cancer specific antigens and antibodies
    Patent number: 11345733
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 31, 2022
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Xiulian Du, Janos Luka, Lewis Joe Stafford, Mark Semenuk, Xue-Ping Wang, Judith Kantor, Andrew Bristol
  • RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS
    Publication number: 20210148915
    Abstract: The present invention encompasses methods of detecting exosomes comprising Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplates is further directed to methods diagnosing cancer by identifying exosomes comprising HAAH.
    Type: Application
    Filed: December 1, 2017
    Publication date: May 20, 2021
    Inventors: Mark Semenuk, Hossein Ghanbari, Michael Lebowitz
  • COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES
    Publication number: 20190322720
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Application
    Filed: November 30, 2018
    Publication date: October 24, 2019
    Inventors: Xiulian DU, Janos LUKA, Lewis Joe STAFFORD, Mark Semenuk, Xue-Ping WANG, Judith KANTOR, Andrew BRISTOL
  • HAAH and MMP-9 are Complementary Cancer Biomarkers and Predictors of Metastasis when Combined
    Publication number: 20190049455
    Abstract: The present disclosure relates to methods of using biomarkers as early disease and patient outcome predictors. More particularly, the present disclosure encompasses methods of predicting cancer metastasis by detecting and/or quantifying aspartyl (asparaginyl) beta hydroxylase (HAAH) and matrix metalloproteinase 9 (MMP9) in a biological sample.
    Type: Application
    Filed: August 8, 2018
    Publication date: February 14, 2019
    Inventors: Hossein Ghanbari, Mark Semenuk
  • RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS
    Publication number: 20180203013
    Abstract: The present invention encompasses methods of detecting exosomes comprising Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplates is further directed to methods diagnosing cancer by identifying exosomes comprising HAAH.
    Type: Application
    Filed: December 1, 2017
    Publication date: July 19, 2018
    Inventors: Mark Semenuk, Hossein Ghanbari, Michael Lebowitz
  • RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS
    Publication number: 20160077098
    Abstract: The present invention encompasses methods of detecting exosomes comprising Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplates is further directed to methods diagnosing cancer by identifying exosomes comprising HAAH.
    Type: Application
    Filed: September 14, 2015
    Publication date: March 17, 2016
    Inventors: Mark Semenuk, Hossein Ghanbari, Michael Lebowitz
  • COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES
    Publication number: 20130189268
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Application
    Filed: June 22, 2011
    Publication date: July 25, 2013
    Applicant: Precision Biologics, Inc.
    Inventors: Xiulian Du, Janos Luka, Lewis Joe Stafford, Mark Semenuk, Xue-Ping Wang, Judith Kantor, Andrew J. Bristol
  • Medical swab device
    Patent number: 5000193
    Abstract: A device is described for expressing liquid absorbed by the tip of a medical swab. The device comprises a barrel and a plunger slidable within the barrel for squeezing the tip of the swab. Liquid is discharged through a flow channel in the container or in the swab shaft. The device is useful particularly to recover small volumes of swab-absorbed liquid where necessary e.g. to carry out clinical essays.
    Type: Grant
    Filed: August 1, 1988
    Date of Patent: March 19, 1991
    Assignee: ADI Diagnostics Inc.
    Inventors: Donald Heelis, Mark Semenuk, Robert Zawydiwski